Miner and colleagues compared a fragment of tau protein measured in blood with brain changes observed after death. The study asked whether people with advanced chronic traumatic encephalopathy, or CTE, had a stronger blood signal. The comparison also shows how much a small set of early cases and overlapping brain pathology can influence what researchers learn.
- Of 21 former male football players who donated their brains, three had no CTE, two had low-stage disease and 16 had high-stage disease at autopsy.
- Median eMTBR-tau was 0.021 pg/mL in the high-stage group and 0.001 pg/mL in the group with no CTE.
- The highest subgroup median occurred among people who also had intermediate or high Alzheimer disease neuropathologic change. The study did not establish a clinical cutoff.
- Paper date
- 19 November 2026
- Sample
- 21 former American football players with paired blood and autopsy data
- Comparison
- CTE stage at autopsy and blood eMTBR-tau during life
Original publication: 19 Nov 2026 · The date above refers to this brief.
How many donors contributed to each CTE stage group?
donors
How a candidate blood marker is compared with pathology
Collect blood during life
Use the closest available research sample before death.
Examine donated brain tissue
Classify CTE stage and assess other pathology.
Compare the groups
Compare concentrations by stage and check results after removing cases with intermediate or high ADNC.
Follow the blood sample to the reference measurement
The authors selected former football players with a research blood sample and a completed brain autopsy. They used the blood sample taken closest to death. For part of the sample, they intentionally included donors with confirmed CTE so they could study more cases. The fraction of donors with CTE describes this selected case series.
Source 1 ↗Early and advanced cases offer different amounts of evidence
There were 16 high-stage cases and two low-stage cases. That is 88.9% high-stage among the 18 CTE cases in the research sample. The median blood concentration was 0.021 pg/mL in the high-stage group and 0.001 pg/mL in the two-person low-stage group. Assessing whether early cases can be distinguished reliably would require many more donors with early pathology and comparable participants without it.
Source 1 ↗Alzheimer disease pathology changed the context
Five participants had CTE and intermediate or high Alzheimer disease neuropathologic change, or ADNC. Their median eMTBR-tau was 0.082 pg/mL. The median was 0.009 pg/mL for the 11 donors with high-stage CTE without intermediate or high ADNC. The authors also reported that a high-stage CTE association persisted when they excluded the five donors with ADNC. The groups were small and could differ in other ways, including age.
Source 1 ↗A larger tau study answered a different question
Brum and colleagues examined eMTBR-tau in 728 participants across two autopsy and two brain imaging cohorts. The study connected the blood signal with advanced tau pathology using different reference measurements. Together, the papers raise a question for future work. How well does the signal distinguish CTE from other conditions that can also produce tau tangles?
Source 1 ↗Source 2 ↗What would establish the accuracy of a blood marker?
A validation study would recruit a broader sample, prespecify a threshold and compare the blood result with pathology across early and advanced cases. It would also include donors with Alzheimer disease pathology and no CTE. That design could estimate how often the assay identifies CTE and how often a result is positive in someone with another condition.
Source 1 ↗The comparison depends on stage, selection and other pathology
Original journal article. Checked the case selection, methods, Tables 1 and 2, results, comparison with Alzheimer disease pathology and limitations.
01Does this sample establish the population prevalence of CTE?
- What was observed
- The selected donor study included 18 CTE cases and three without CTE.
- Where the conclusion stops
- Some donors were deliberately included to enrich the number of cases. Population prevalence requires a representative denominator.
Source 1 · Methods, Sample and Table 1
02What contributed to the highest median concentration?
- What was observed
- The subgroup with CTE and intermediate or high Alzheimer disease neuropathologic change had the highest reported median.
- Where the conclusion stops
- Larger comparison groups are required to determine specificity for CTE.
Source 1 · Results, Table 2 and Limitations
Numbers you can inspect
| Measure | Value & unit | Origin & method |
|---|---|---|
| Donors | 21 people | Reported Former American football players with blood and autopsy results. Source 1 · Methods and Table 1 |
| Donors with CTE | 18 people | Reported CTE was confirmed on neuropathologic evaluation. Source 1 · Table 1 |
| Donors without CTE | 3 people | Reported Reference count in the case series. Source 1 · Table 1 |
| Low-stage CTE | 2 people | Reported One stage I and one stage II case. Source 1 · Table 1 |
| High-stage CTE | 16 people | Reported Eight stage III and eight stage IV cases. Source 1 · Table 1 |
| High-stage share of CTE cases | 88.9 percent | Calculated 16 divided by 18 times 100, rounded to one decimal. Source 1 · Table 1 |
| High-stage group median | 0.021 pg/mL | Reported Reported median, IQR 0.006 to 0.038. Source 1 · Table 2 |
| No-CTE group median | 0.001 pg/mL | Reported Reported median in three donors. Source 1 · Table 2 |
| CTE with intermediate or high ADNC | 5 people | Reported Subgroup with co-occurring pathology. Source 1 · Results and Table 2 |
| Median with CTE and intermediate or high ADNC | 0.082 pg/mL | Reported Median in the five-donor subgroup. Source 1 · Table 2 |
| Median with high-stage CTE without intermediate or high ADNC | 0.009 pg/mL | Reported Median in the eleven-donor subgroup. Source 1 · Table 2 |
| Separate Brum et al. study | 728 people | Reported 521 autopsy participants and 207 tau-PET participants. Source 2 · Brum et al. Abstract |
Compare the actual experiments
These studies answer different questions. Read the unit and endpoint before comparing results.
| Study | Unit & setting | Readout | Interpretation boundary |
|---|---|---|---|
| Tau assay and reference measurements Source 2 · Brum et al. Abstract | Brain donors and tau-PET participants | Blood eMTBR-tau compared with pathology or imaging | Assay performance depends on the condition and the reference measurement under study. |
| An association and a useful clinical endpoint Source 1 · Miner et al. Discussion and Limitations | Autopsy groups and surrogate outcomes across studies | Tau concentration and tissue pathology | A measurable signal still needs validation for a defined clinical use. |
The export includes claims, available numbers, methods and source locations. It contains our reading notes and published summaries; it is not raw participant data or an independent reanalysis.
Evidence update · 21 Nov 2026
First publication. Any calculations in this brief use reported figures. The reading notes identify possible follow-up questions. AI source check; no human editorial or clinical review.
The stage-by-stage comparison in the 21 donors
| Autopsy finding | Donors | Median eMTBR-tau, pg/mL (IQR) |
|---|---|---|
| No CTE | 3 | 0.001 (0.001 to 0.001) |
| Low-stage CTE | 2 | 0.001 (0.001 to 0.002) |
| High-stage CTE | 16 | 0.021 (0.006 to 0.038) |
Group sizes and medians come from Table 2. The IQR describes the middle half of measured values within each group.
Your questions, answered
Does 18 of 21 give a rate for all former football players?
The study includes donors selected through research and brain donation. Some were included because they had confirmed CTE. The count describes the study sample.
Could the study tell how well the marker detects early CTE?
There were two low-stage cases. The authors identify reliable evaluation of early disease as a question for larger studies.
What does ADNC mean in the table and article?
ADNC is Alzheimer disease neuropathologic change. The highlighted subgroup had intermediate or high ADNC along with CTE.
What does the second study add?
Brum and colleagues assessed how the assay relates to tau pathology in separate autopsy and imaging cohorts. That helps motivate tests of whether it distinguishes the cause of the tau signal.
Limits of this interpretation
- The case series was selected through research participation and brain donation. All donors were men and former American football players.
- There were just two low-stage cases and three comparison donors without CTE. The sample was too small for age adjustment.
- The study lacked an Alzheimer disease comparison group without CTE. Reliable diagnostic accuracy estimates would require a broader sample.
Sources & transparency
- Miner, Stein, McKee et al. (2026) — Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology
Original journal article. Checked the case selection, methods, Tables 1 and 2, results, comparison with Alzheimer disease pathology and limitations. · Accessed 21 Nov 2026
DOI: 10.1001/jama.2026.24780 - Brum, Janelidze, Singh et al. (2026) — A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology
Original study, checked the abstract and cohort counts as a separate comparison for eMTBR-tau in autopsy and PET cohorts. · Accessed 21 Nov 2026
DOI: 10.1001/jama.2026.25143
Prepared and source-checked with AI for Press-news Team. The source notes identify the material available during preparation. The article received no human editorial or clinical review. The source list supports the reported results and the calculations shown.
Source check: AI source check — primary research and stated source limits
Clinical review: Not applicable to this educational guide
Suggest a correction